Search form

 

Press Releases


Please select a year to review:
           

2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004

2004

December 15, 2004
Axcan's High Dose Safety Study on ITAX in Healthy Subjects Shows No Cardiac Adverse Drug Reaction - Results of a large, high dose, electrocardiogram trial completed in 162 healthy subjects

November 10, 2004
Axcan Reports Fourth Quarter and Fiscal 2004 Results-Revenue Up 36% to $243.6 Million and Diluted EPS Up 34% to $0.98

November 09, 2004
1-Gram Mesalamine Suppository Approved in the U.S. for the Treatment of Ulcerative Proctitis

November 03, 2004
Axcan Announces Conference Call and Web Cast for Fourth Quarter and Fiscal 2004 Results

November 02, 2004
Axcan Launches URSO Forte™ in the U.S.

November 01, 2004
Axcan Pharma to Present at CIBC World Markets Fifteenth Annual Healthcare Conference in New York

October 22, 2004
Axcan Pharma to present at C.E. Unterberg, Towbin Specialty Pharmaceutical Conference in New York

September 23, 2004
Axcan Pharma to Present at CIBC World Markets Frontenac Institutional Investor Conference in Quebec City

September 16, 2004
Axcan inaugurates expanded Mont Saint-Hilaire head office premises

September 14, 2004
MEDIA ADVISORY - Axcan Pharma to Inaugurate New CAN $15-Million Expansion of Headquarters in Mont-Saint-Hilaire

September 09, 2004
Axcan Pharma to Host Analyst / Investor Luncheon at Newly Expanded Head Office in Mont-St-Hilaire

August 05, 2004
Axcan Reports Third Quarter 2004 Results - Revenue Up 32.3% to $62.0 Million

July 26, 2004
URSO 500 mg Tablets Approved in the U.S. for the Treatment of Primary Biliary Cirrhosis

July 21, 2004
Axcan announces conference call and web cast for third quarter of fiscal 2004 results

June 21, 2004
Axcan to present at the TSX Canada day in New York 2004

May 21, 2004
Axcan to Present at the UBS Global Specialty Pharmaceuticals Conference in New York City

May 20, 2004
Axcan Announces Positive Phase II Efficacy and Safety Results for ITAX in the Treatment of Functional Dyspepsia

May 18, 2004
Axcan Announces Positive Study for the New Sulfated Version of Ursodiol as a Potent Chemopreventive Agent in Colorectal Cancer

May 13, 2004
Axcan Initiates Phase III Clinical Trials on ITAX - Functional Dyspepsia Studies to be Carried Out in North America and Western Europe

May 06, 2004
Axcan Reports Second Quarter 2004 Results - Revenue up 38.6% to $63.2 million-net Income Rises 39.3%

April 22, 2004
Axcan Announces Conference Call and Web Cast for Second Quarter of Fiscal 2004 Results

April 21, 2004
Axcan Pharma to present at CIBC World Markets Annual Biotechnology and Speciality Pharmaceuticals Conference in New York City

March 30, 2004
Axcan Receives European Approval of PHOTOBARR for the Ablation of High-Grade Dysplasia Associated With Barrett's Esophagus

March 29, 2004
Axcan Pharma to Present at Scotia Capital Growth Conference in Montreal

February 19, 2004
Annual General Meeting of Shareholders : Following Major Acquisitions Axcan Sees Period of Strong Growth for Fiscal 2004 and Beyond

February 05, 2004
Axcan Reports Strong First Quarter 2004 Results Revenue Up 52% to $57.6 Million

January 27, 2004
Axcan Pharma to Present at Merrill Lynch Healthcare Conference in New York

January 26, 2004
Axcan Announces Conference Call And Web Cast For First Quarter Of Fiscal 2004 Results

January 22, 2004
Axcan Pharma Reports Positive Pre-Ind Meeting For ITAX - Functional Dyspepsia Phase III Studies to be Initiated Upon Ind Filing

January 19, 2004
Axcan Pharma Announces Details for its Annual General Meeting

January 15, 2004
Axcan Pharma to Host Analyst/Investor Luncheons in New-York and Montreal

January 14, 2004
Axcan Submits 1 g Mesalamine Suppositories for Approval in the U.S. for the Treatment of Ulcerative Proctitis

January 09, 2004
Axcan Pharma to Present at JP Morgan Healthcare Conference in San Francisco

January 07, 2004
Axcan Restates And Increases Diluted Income Per Share For Fiscal 2003